Edition:
United States

Akcea Therapeutics Inc (AKCA.OQ)

AKCA.OQ on NASDAQ Stock Exchange Global Select Market

19.98USD
20 Feb 2018
Change (% chg)

$-1.90 (-8.68%)
Prev Close
$21.88
Open
$21.88
Day's High
$22.71
Day's Low
$19.58
Volume
85,617
Avg. Vol
96,404
52-wk High
$31.23
52-wk Low
$8.10

Select another date:

Wed, Feb 7 2018

BRIEF-Akcea Completes Enrollment In Phase 2B Study Of Akcea-Apo(A)-LRx

* AKCEA COMPLETES ENROLLMENT IN PHASE 2B STUDY OF AKCEA-APO(A)-LRX Source text for Eikon: Further company coverage:

BRIEF-Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen

* Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen for the treatment of FCS

BRIEF-Akcea Therapeutics Q3 loss per share $0.27

* Q3 earnings per share view $-0.19, revenue view $11.9 million -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-AKCEA PRESENTS DATA DEMONSTRATING SIGNIFICANT BURDEN OF ILLNESS IN FAMILIAL CHYLOMICRONEMIA SYNDROME

* AKCEA PRESENTS DATA DEMONSTRATING SIGNIFICANT BURDEN OF ILLNESS IN FAMILIAL CHYLOMICRONEMIA SYNDROME Source text for Eikon: Further company coverage:

BRIEF-Akcea and Ionis announce filing of new drug submission for Volanesorsen to Health Canada

* Akcea and Ionis announce filing of new drug submission for volanesorsen to Health Canada

BRIEF-Akcea Therapeutics establishes Canadian subsidiary

* Akcea Therapeutics Inc - Establishment of Ottawa-based Canadian unit and appointment of Jared Rhines as general manager for Akcea Therapeutics Canada Source text for Eikon: Further company coverage:

BRIEF-Akcea Therapeutics says co announced Mike Maclean joins as CFO, effective August 31

* Akcea Therapeutics says on Sept 5, co announced Mike Maclean joined company as Chief Financial Officer, effective August 31- SEC filing Source text for Eikon: [http://bit.ly/2eIZHLj] Further company coverage:

BRIEF-Akcea and Ionis submits New Drug Application for volanesorsen to FDA

* Akcea and Ionis announce submission of new drug application for volanesorsen to the U.S. FDA

Select another date: